A carregar...
Potential use of custirsen to treat prostate cancer
Over the last few years, five agents have demonstrated a survival benefit over a comparator treatment or placebo in the treatment of metastatic castration-resistant prostate cancer and have been approved by the US Food and Drug Administration: sipuleucel-T (a dendritic cell immunotherapy); cabazitax...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3699352/ https://ncbi.nlm.nih.gov/pubmed/23836992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S33077 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|